Veteran Peer Navigators for Prostate Cancer Screening Decisions

This study is looking at a program called "Veteran Peer Decision Coaching Session for PSA Screening" to help Veterans make informed choices about prostate cancer screening. Prostate-specific antigen (PSA) screening can find prostate cancer, but it also has downsides, like finding cancers that might not need treatment. This study wants to see if having a Veteran peer (someone with similar experiences) guide you through the decision-making process can help you understand the pros and cons better. They will measure how confident you feel about your decision, how much you know about prostate cancer screening, and the quality of your decision. They plan to enroll 228 men, aged 40-69, who are Veterans and receive primary care at VANYHHS-Manhattan.

Study design
This is an interventional study planning to enroll 228 participants. The study is not blinded, meaning participants will know if they are receiving the peer coaching.
What's involved
Participants in the intervention group will have a structured interview with a Veteran Peer Decision Coach to review information about prostate cancer risk and screening.
Compensation
Not stated in the trial record.
Follow-up
Your decisional conflict will be measured up to 3 months after the coaching session. Your knowledge and decision quality will be measured on Day 1.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06549036

Veteran Peer Navigators to Promote Shared Decision Making for PSA Screening

Not Yet Recruiting
NAAges 40–69InterventionalScreening
VA Office of Research and Development
~228 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Veteran Peer Decision Coaching Session for PSA Screening

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decisional Conflict
Measured over Up to 3 months
+5 more outcomes measured
Prostate Cancer
1 sites across 1 states
New York1
  • Danil V Makarov, MD MHS · PRINCIPAL_INVESTIGATOR · VA NY Harbor Healthcare System, New York, NY

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Veteran
Male
Attending VANYHHS-Manhattan for routine primary care appointment
Primary care provider at VA New York Harbor Healthcare System (VANYHHS)

Exclusion

Patients seen within 9 months of other PSA tests
Patients seen within 180 days after primary diagnosis of urinary obstruction, prostatitis, hematuria, other disorder of prostate, unexplained weight loss, or lumbar back pain
Patients with a prior diagnosis of prostate cancer (ICD-10-CM C61)
Patients visiting their provider for any indication other than a well-visit appointment
  • Decisional ConflictUp to 3 months

    The 16-item Decisional Conflict Scale (DCS) measures Veterans' perceptions of 1) uncertainty in choosing options, 2) feelings of having adequate knowledge and clear values, and 3) effective decision making. DCS is scored on a 5-point Likert scales with scores ranging from 0 (no decisional conflict) to 100 (extremely high decisional conflict)

  • Patient Knowledge Survey ScoreDay 1

    The Patient Knowledge Survey comprises of 12-items assessing prostate cancer and PSA screening knowledge. Respondents provide an answer of "True", "Unsure", or "False". The total score is the sum of correct responses and ranges from 0 - 12 with higher scores indicating greater knowledge levels.

  • Decision Quality ScoreDay 1

    Decision quality will be measured through 3 domains: 1) decisional conflict 2) being informed (e.g. accurate understanding about screening and its risks and benefits) and 3) making preference-concordant decisions (i.e. treatment consistent with patient preferences). The Decision Quality Balance Scale consists of 12 questions (6 Pros and 6 Cons of testing) scored on a 5 point Likert scale (Strongly Disagree to Strongly Agree) that represents the relative strengths of the pros versus the cons and ranges from -24 to +24. A high quality decision is when patients are both well-informed and making preference-concordant decisions (i.e. treatment consistent with patient preferences as determined by responses to survey questions).

  • Prostate-specific Antigen (PSA) Screening RatesUp to Month 3

    Percentage of participants who receive at least one PSA screening test. Screening data is collected through patient self-report and electronic health record data.

  • Percentage of Participants Who Make Informed Choice (Knowledge Survey + Measure of Informed Choice Attitudes Scale)Day 1

    The percentage of participants who make an informed choice to either undergo or decline PSA testing. Informed choices are those in which: 1\. Men with good knowledge and positive measure of informed choice attitudes (\> or = 22) choose to undergo the test OR 2) Men with good knowledge but negative measure of informed choice attitudes (\<22) towards the test, do not undergo the test.

  • Measure of Informed Choice Attitudes ScaleDay 1

    The measure of Informed Choice evaluates the screening decision. The 4-item measure consists of items assessing knowledge, attitude towards the screening test, and a record of test uptake. The questions are graded on a 7 point Likert-type scale (1 to 7) with scores ranging from 4 to 28. The median of 22 was taken to classify men's attitudes as positive or negative, with scores 22 or above indicating positive attitudes, and those below 22 indicating negative attitudes.